EU approval for GSK's Incruse as Anoro waits in wings
This article was originally published in Scrip
The European Commission has approved GlaxoSmithKline's once-daily, maintenance bronchodilator treatment Incruse (umeclidinium 55mcg) to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD), following a recommendation by the CHMP in February (scripintelligence.com, 21 February 2014).
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.